SDGR
Schrödinger, Inc.

Schrödinger, Inc.SDGR

Healthcare · Health Information Services
29.82USD
+3.65%
Nov 09, 2026
SDGR overview ready
Physics-Based Computational Molecular Discovery Software and Drug Programs
Schrödinger is a computational molecular-discovery platform vendor and drug-discovery collaborator.
Theme not measured
Drug-Discovery Simulation Software has no leadership state this session.
An early price trend
Longer-term context reads early trend, with a near-term setup of daily advance.
Demanding valuation
The price embeds expectations that run ahead of the cash it currently generates.
Fundamentals not measured
Primary risk
Dependence on continued adoption of computational methods in pharma R&D.
Market Nov 6Filing Sep 30Price action Nov 8Research Oct 22

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction7.1BusinessPerformance5.0BusinessQuality3.5Valuation0.3ThemeMomentum—Mixed — Revenue growth has accelerated, rising from -1.6% to +19% year over year. One recent quarter could not be confirmed and is not part of this read. The company is still loss-making: the diluted loss per share widened to -$0.50 from -$0.45 a year earlier. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
Drug-Discovery Simulation Software — Drug-Discovery Simulation Software has only one or two priced members — no leadership state
Its economic family, Biotechnology, reads Improving (+5.9pp vs SPY) — the family’s reading, not this theme’s.
Price
Loading price history…

Price Action

An early price trend
Longer-term context reads early trend, with a near-term setup of daily advance.
EntryBreakout + retest

Price broke through the weekly SMA200, then retested it constructively and recovered — a fresh structural entry rather than a chase.

Key Financials

Market Cap
$1.9B
Avg Volume (60D)
2.4M
60 sessions
Revenue Growth YoY
+23.3%
FY2025 vs FY2024
Gross Margin
+58.5%
Trailing twelve months
Operating Margin
-49.6%
Trailing twelve months
Free Cash Flow Yield
-6.2%
Distance from 200DMA
+75.0%
P/E
N/M
Market metrics as of Nov 6, 2026
Financial results for the period ended Sep 30, 2026
Filed balance-sheet data as of Sep 30, 2026

Business Performance

Mixed

Revenue growth has accelerated, rising from -1.6% to +19% year over year. One recent quarter could not be confirmed and is not part of this read. The company is still loss-making: the diluted loss per share widened to -$0.50 from -$0.45 a year earlier.

Latest reported: Q3 FY2026, ended Sep 30
Revenue growthAccelerating
+19%
$64.5M in Q3 FY2026 · YoY
YoY growth, last 4 quarters
  1. n/a
  2. -1.6%
  3. +7.5%
  4. +19%
Earnings growthLoss widening
-$0.50
Diluted EPS -$0.50 vs -$0.45 a year earlier · GAAP
Too few comparable EPS quarters: a loss or a turn to profit has no meaningful percentage.
Operating marginExpanding
-40.5%
+44.1 pp YoY · gross margin 59.3% (+7.7 pp)

Business Quality

3.5 / 10

How well the business earns on its assets, converts earnings to cash and funds itself — read from its SEC filings.

Fundamentals & Valuation

Both valuation perspectives agree this company is expensive.
Schrödinger, Inc. has an Expensive valuation stance because the price embeds expectations that run ahead of the cash it currently generates.

Company Research

Thesis
Schrödinger is a computational molecular-discovery platform vendor and drug-discovery collaborator. It sells hosted and enterprise scientific software while applying its physics-based simulation and AI capabilities to partnered and proprietary small-molecule programs.
Opportunity
Moderate opportunity
Pharmaceutical and biotechnology R&D adoption of computational simulation, machine learning, and automated molecular-design workflows to improve hit discovery, lead optimization, and candidate selection before costly wet-lab and clinical work.
Key risk
Dependence on continued adoption of computational methods in pharma R&D.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Health Information Services
What they do

Schrödinger develops and sells physics-based computational software platforms for molecular discovery and applies these capabilities to drug discovery programs both internally and through collaborations.

How it earns

Revenue is generated primarily through software licensing and collaborative drug discovery agreements.

Products & services
Computational molecular discovery software
Preclinical and clinical drug discovery programs
Customers & end markets
Pharmaceutical and biotechnology companies
Materials science industries
Market position

Niche leader in physics-based and AI-driven molecular discovery platforms.

Demand drivers
Medium cyclicality

Demand is influenced by pharmaceutical R&D budgets and innovation cycles, which can fluctuate with economic conditions.